頭孢曲松 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "頭孢曲松" in Chinese language version.

refsWebsite

Global rank Chinese rank

29nih.gov

4^th place

5^th place

23doi.org

2^nd place

23^rd place

18web.archive.org

1^st place

8semanticscholar.org

11^th place

332^nd place

4archive.org

6^th place

4^th place

2drugs.com

399^th place

208^th place

2books.google.com

3^rd place

8^th place

2harvard.edu

18^th place

57^th place

2aap.org

low place

5,304^th place

1tga.gov.au

3,984^th place

1,603^rd place

1handle.net

102^nd place

492^nd place

1worldcat.org

5^th place

12^th place

1gov.uk

432^nd place

770^th place

1fda.gov

447^th place

581^st place

1medscape.com

719^th place

889^th place

1utah.edu

2,446^th place

2,114^th place

1alsconsortium.org

low place

aap.org

publications.aap.org

Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W. Ceftriaxone and acute renal failure in children (PDF). Pediatrics. April 2014, 133 (4): e917–e922 [2024-02-22]. PMID 24664092. S2CID 2854637. doi:10.1542/peds.2013-2103. （原始内容存档 (PDF)于2024-02-22）.
Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events (PDF). Pediatrics. April 2009, 123 (4): e609–e613 [2024-02-22]. PMID 19289450. S2CID 22718923. doi:10.1542/peds.2008-3080. （原始内容存档 (PDF)于2024-02-22）.

alsconsortium.org

Statement on the Clinical Trial of Ceftriaxone. The Northeast ALS Consortium (NEALS). 8 August 2012 [2013-05-10]. （原始内容存档于2013-05-28）.

archive.org

Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology. December 1990, 99 (6): 1772–1778. PMID 2227290. doi:10.1016/0016-5085(90)90486-K.
Scheffers DJ, Pinho MG. Bacterial cell wall synthesis: new insights from localization studies. Microbiology and Molecular Biology Reviews. December 2005, 69 (4): 585–607. PMC 1306805 . PMID 16339737. doi:10.1128/MMBR.69.4.585-607.2005.
Red Book: Pharmacy's Fundamental Reference 114th. PDR Network, LLC. 2010. ISBN 978-1-56363-751-3.
Klein NC, Cunha BA. Third-generation cephalosporins. The Medical Clinics of North America. July 1995, 79 (4): 705–719. PMID 7791418. doi:10.1016/s0025-7125(16)30034-7 .

books.google.com

Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 495. ISBN 978-3-527-60749-5.
Nursing Pharmacology Made Incredibly Easy!. Lippincott Williams & Wilkins. 7 March 2012: 496. ISBN 978-1-4511-4624-0. （原始内容存档于2016-06-03）.

doi.org

Beam TR. Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life. Pharmacotherapy. 1985, 5 (5): 237–253. PMID 3906584. S2CID 25559476. doi:10.1002/j.1875-9114.1985.tb03423.x.
St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, Torrone E, Weinstock H, Kersh EN, Thorpe P. Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. MMWR. Morbidity and Mortality Weekly Report. December 2020, 69 (50): 1911–1916. PMC 7745960 . PMID 33332296. doi:10.15585/mmwr.mm6950a6.
Di Bella S, Gatti M, Principe L. Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?. European Journal of Clinical Microbiology & Infectious Diseases. 2023-04-23, 42 (7): 917–918. ISSN 1435-4373. PMID 37119346. S2CID 258423746. doi:10.1007/s10096-023-04612-x （英语）.
Palzkill T. Metallo-β-lactamase structure and function. Ann N Y Acad Sci. January 2013, 1277 (1): 91–104. Bibcode:2013NYASA1277...91P. PMC 3970115 . PMID 23163348. doi:10.1111/j.1749-6632.2012.06796.x.
Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology. December 1990, 99 (6): 1772–1778. PMID 2227290. doi:10.1016/0016-5085(90)90486-K.
Shrimali JD, Patel HV, Gumber MR, Kute VB, Shah PR, Vanikar AV, Trivedi HL. Ceftriaxone induced immune hemolytic anemia with disseminated intravascular coagulation. Indian Journal of Critical Care Medicine. November 2013, 17 (6): 394–395. PMC 3902580 . PMID 24501497. doi:10.4103/0972-5229.123465 .
Guleria VS, Sharma N, Amitabh S, Nair V. Ceftriaxone-induced hemolysis. Indian Journal of Pharmacology. Sep–Oct 2013, 45 (5): 530–531. PMC 3793531 . PMID 24130395. doi:10.4103/0253-7613.117758 .
Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W. Ceftriaxone and acute renal failure in children (PDF). Pediatrics. April 2014, 133 (4): e917–e922 [2024-02-22]. PMID 24664092. S2CID 2854637. doi:10.1542/peds.2013-2103. （原始内容存档 (PDF)于2024-02-22）.
Patel KB, Nicolau DP, Nightingale CH, Quintiliani R. Pharmacokinetics of cefotaxime in healthy volunteers and patients. Diagnostic Microbiology and Infectious Disease. May 1995, 22 (1–2): 49–55. PMID 7587050. doi:10.1016/0732-8893(95)00072-I.
Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events (PDF). Pediatrics. April 2009, 123 (4): e609–e613 [2024-02-22]. PMID 19289450. S2CID 22718923. doi:10.1542/peds.2008-3080. （原始内容存档 (PDF)于2024-02-22）.
van Heijenoort J. Formation of the glycan chains in the synthesis of bacterial peptidoglycan. Glycobiology. March 2001, 11 (3): 25R–36R. PMID 11320055. S2CID 46066256. doi:10.1093/glycob/11.3.25r .
Scheffers DJ, Pinho MG. Bacterial cell wall synthesis: new insights from localization studies. Microbiology and Molecular Biology Reviews. December 2005, 69 (4): 585–607. PMC 1306805 . PMID 16339737. doi:10.1128/MMBR.69.4.585-607.2005.
Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clinical Microbiology Reviews. October 2010, 23 (4): 858–883. PMC 2952976 . PMID 20930076. doi:10.1128/CMR.00007-10.
Arvidsson A, Alván G, Angelin B, Borgå O, Nord CE. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. The Journal of Antimicrobial Chemotherapy. September 1982, 10 (3): 207–215. PMID 6292158. doi:10.1093/jac/10.3.207.
Blumer J. Pharmacokinetics of ceftriaxone. Hospital Practice. September 1991, 26 (Suppl 5): 7–13; discussion 52–4. PMID 1918224. doi:10.1080/21548331.1991.11707737.
Balant L, Dayer P, Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. Clinical Pharmacokinetics. 1985-04-01, 10 (2): 101–143. PMID 3888488. S2CID 23478077. doi:10.2165/00003088-198510020-00001.
Klein NC, Cunha BA. Third-generation cephalosporins. The Medical Clinics of North America. July 1995, 79 (4): 705–719. PMID 7791418. doi:10.1016/s0025-7125(16)30034-7 .
Schichor A, Bernstein B, Weinerman H, Fitzgerald J, Yordan E, Schechter N. Lidocaine as a diluent for ceftriaxone in the treatment of gonorrhea. Does it reduce the pain of the injection?. Archives of Pediatrics & Adolescent Medicine. January 1994, 148 (1): 72–75. PMID 8143016. doi:10.1001/archpedi.1994.02170010074017.
Knackstedt LA, Melendez RI, Kalivas PW. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biological Psychiatry. January 2010, 67 (1): 81–84. PMC 2795043 . PMID 19717140. doi:10.1016/j.biopsych.2009.07.018.
Verma R, Mishra V, Sasmal D, Raghubir R. Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury. European Journal of Pharmacology. July 2010, 638 (1–3): 65–71. PMID 20423712. doi:10.1016/j.ejphar.2010.04.021.
Lee SG, Su ZZ, Emdad L, Gupta P, Sarkar D, Borjabad A, Volsky DJ, Fisher PB. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. The Journal of Biological Chemistry. May 2008, 283 (19): 13116–13123. PMC 2442320 . PMID 18326497. doi:10.1074/jbc.M707697200 .
Hedlund E. The protective effects of β-lactam antibiotics in motor neuron disorders. Experimental Neurology. September 2011, 231 (1): 14–18. PMID 21693120. S2CID 26353910. doi:10.1016/j.expneurol.2011.06.002.
Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. January 2005, 433 (7021): 73–77. Bibcode:2005Natur.433...73R. PMID 15635412. S2CID 4301666. doi:10.1038/nature03180.

drugs.com

Ceftriaxone (Rocephin) Use During Pregnancy. Drugs.com. 2019-12-12 [2019-12-24]. （原始内容存档于2016-08-23）.
Ceftriaxone Sodium Monograph for Professionals. Drugs.com. [2016-08-27]. （原始内容存档于2016-05-31）.

fda.gov

accessdata.fda.gov

Rocephin Prescribing Information (PDF). Roche. [2015-11-01]. （原始内容存档 (PDF)于2016-03-04）.

gov.uk

Ceftriaxone (Rocephin): Incompatible with solutions containing calcium. （原始内容存档于2023-12-08）.

handle.net

hdl.handle.net

World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

harvard.edu

ui.adsabs.harvard.edu

Palzkill T. Metallo-β-lactamase structure and function. Ann N Y Acad Sci. January 2013, 1277 (1): 91–104. Bibcode:2013NYASA1277...91P. PMC 3970115 . PMID 23163348. doi:10.1111/j.1749-6632.2012.06796.x.
Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. January 2005, 433 (7021): 73–77. Bibcode:2005Natur.433...73R. PMID 15635412. S2CID 4301666. doi:10.1038/nature03180.

medscape.com

The Use of Cephalosporins in Penicillin-allergic Patients. www.medscape.com. [2015-11-10]. （原始内容存档于2015-11-14）.

nih.gov

ncbi.nlm.nih.gov

Beam TR. Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life. Pharmacotherapy. 1985, 5 (5): 237–253. PMID 3906584. S2CID 25559476. doi:10.1002/j.1875-9114.1985.tb03423.x.
St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, Torrone E, Weinstock H, Kersh EN, Thorpe P. Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. MMWR. Morbidity and Mortality Weekly Report. December 2020, 69 (50): 1911–1916. PMC 7745960 . PMID 33332296. doi:10.15585/mmwr.mm6950a6.
Di Bella S, Gatti M, Principe L. Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?. European Journal of Clinical Microbiology & Infectious Diseases. 2023-04-23, 42 (7): 917–918. ISSN 1435-4373. PMID 37119346. S2CID 258423746. doi:10.1007/s10096-023-04612-x （英语）.
Palzkill T. Metallo-β-lactamase structure and function. Ann N Y Acad Sci. January 2013, 1277 (1): 91–104. Bibcode:2013NYASA1277...91P. PMC 3970115 . PMID 23163348. doi:10.1111/j.1749-6632.2012.06796.x.
Ceftriaxone. Drugs and Lactation Database (LactMed®) [Internet]. 2021-01-18 [2024-08-03]. （原始内容存档于2024-06-03）.
Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology. December 1990, 99 (6): 1772–1778. PMID 2227290. doi:10.1016/0016-5085(90)90486-K.
Shrimali JD, Patel HV, Gumber MR, Kute VB, Shah PR, Vanikar AV, Trivedi HL. Ceftriaxone induced immune hemolytic anemia with disseminated intravascular coagulation. Indian Journal of Critical Care Medicine. November 2013, 17 (6): 394–395. PMC 3902580 . PMID 24501497. doi:10.4103/0972-5229.123465 .
Guleria VS, Sharma N, Amitabh S, Nair V. Ceftriaxone-induced hemolysis. Indian Journal of Pharmacology. Sep–Oct 2013, 45 (5): 530–531. PMC 3793531 . PMID 24130395. doi:10.4103/0253-7613.117758 .
Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W. Ceftriaxone and acute renal failure in children (PDF). Pediatrics. April 2014, 133 (4): e917–e922 [2024-02-22]. PMID 24664092. S2CID 2854637. doi:10.1542/peds.2013-2103. （原始内容存档 (PDF)于2024-02-22）.
Patel KB, Nicolau DP, Nightingale CH, Quintiliani R. Pharmacokinetics of cefotaxime in healthy volunteers and patients. Diagnostic Microbiology and Infectious Disease. May 1995, 22 (1–2): 49–55. PMID 7587050. doi:10.1016/0732-8893(95)00072-I.
Guggenbichler JP, Allerberger FJ, Dierich M. Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy. Padiatrie und Padologie. 1986, 21 (4): 335–342 [2023-04-29]. PMID 3562044. （原始内容存档于2023-04-29）.
Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events (PDF). Pediatrics. April 2009, 123 (4): e609–e613 [2024-02-22]. PMID 19289450. S2CID 22718923. doi:10.1542/peds.2008-3080. （原始内容存档 (PDF)于2024-02-22）.
van Heijenoort J. Formation of the glycan chains in the synthesis of bacterial peptidoglycan. Glycobiology. March 2001, 11 (3): 25R–36R. PMID 11320055. S2CID 46066256. doi:10.1093/glycob/11.3.25r .
Scheffers DJ, Pinho MG. Bacterial cell wall synthesis: new insights from localization studies. Microbiology and Molecular Biology Reviews. December 2005, 69 (4): 585–607. PMC 1306805 . PMID 16339737. doi:10.1128/MMBR.69.4.585-607.2005.
Patel IH, Kaplan SA. Pharmacokinetic profile of ceftriaxone in man. The American Journal of Medicine. October 1984, 77 (4C): 17–25. PMID 6093513.
Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clinical Microbiology Reviews. October 2010, 23 (4): 858–883. PMC 2952976 . PMID 20930076. doi:10.1128/CMR.00007-10.
Arvidsson A, Alván G, Angelin B, Borgå O, Nord CE. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. The Journal of Antimicrobial Chemotherapy. September 1982, 10 (3): 207–215. PMID 6292158. doi:10.1093/jac/10.3.207.
Blumer J. Pharmacokinetics of ceftriaxone. Hospital Practice. September 1991, 26 (Suppl 5): 7–13; discussion 52–4. PMID 1918224. doi:10.1080/21548331.1991.11707737.
Balant L, Dayer P, Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. Clinical Pharmacokinetics. 1985-04-01, 10 (2): 101–143. PMID 3888488. S2CID 23478077. doi:10.2165/00003088-198510020-00001.
Klein NC, Cunha BA. Third-generation cephalosporins. The Medical Clinics of North America. July 1995, 79 (4): 705–719. PMID 7791418. doi:10.1016/s0025-7125(16)30034-7 .
Schichor A, Bernstein B, Weinerman H, Fitzgerald J, Yordan E, Schechter N. Lidocaine as a diluent for ceftriaxone in the treatment of gonorrhea. Does it reduce the pain of the injection?. Archives of Pediatrics & Adolescent Medicine. January 1994, 148 (1): 72–75. PMID 8143016. doi:10.1001/archpedi.1994.02170010074017.
Knackstedt LA, Melendez RI, Kalivas PW. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biological Psychiatry. January 2010, 67 (1): 81–84. PMC 2795043 . PMID 19717140. doi:10.1016/j.biopsych.2009.07.018.
Verma R, Mishra V, Sasmal D, Raghubir R. Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury. European Journal of Pharmacology. July 2010, 638 (1–3): 65–71. PMID 20423712. doi:10.1016/j.ejphar.2010.04.021.
Lee SG, Su ZZ, Emdad L, Gupta P, Sarkar D, Borjabad A, Volsky DJ, Fisher PB. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. The Journal of Biological Chemistry. May 2008, 283 (19): 13116–13123. PMC 2442320 . PMID 18326497. doi:10.1074/jbc.M707697200 .
Hedlund E. The protective effects of β-lactam antibiotics in motor neuron disorders. Experimental Neurology. September 2011, 231 (1): 14–18. PMID 21693120. S2CID 26353910. doi:10.1016/j.expneurol.2011.06.002.
Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. January 2005, 433 (7021): 73–77. Bibcode:2005Natur.433...73R. PMID 15635412. S2CID 4301666. doi:10.1038/nature03180.

dailymed.nlm.nih.gov

Ceftriaxone- ceftriaxone sodium injection, powder, for solution. DailyMed. 2019-12-31 [2020-02-01]. （原始内容存档于2015-11-17）.
DailyMed – Search Results for ceftriaxone. dailymed.nlm.nih.gov. [2015-11-04]. （原始内容存档于2016-03-06）.

pubmed.ncbi.nlm.nih.gov

Guggenbichler JP, Allerberger FJ, Dierich M. Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy. Padiatrie und Padologie. 1986, 21 (4): 335–342 [2023-04-29]. PMID 3562044. （原始内容存档于2023-04-29）.

semanticscholar.org

api.semanticscholar.org

Beam TR. Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life. Pharmacotherapy. 1985, 5 (5): 237–253. PMID 3906584. S2CID 25559476. doi:10.1002/j.1875-9114.1985.tb03423.x.
Di Bella S, Gatti M, Principe L. Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?. European Journal of Clinical Microbiology & Infectious Diseases. 2023-04-23, 42 (7): 917–918. ISSN 1435-4373. PMID 37119346. S2CID 258423746. doi:10.1007/s10096-023-04612-x （英语）.
Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W. Ceftriaxone and acute renal failure in children (PDF). Pediatrics. April 2014, 133 (4): e917–e922 [2024-02-22]. PMID 24664092. S2CID 2854637. doi:10.1542/peds.2013-2103. （原始内容存档 (PDF)于2024-02-22）.
Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events (PDF). Pediatrics. April 2009, 123 (4): e609–e613 [2024-02-22]. PMID 19289450. S2CID 22718923. doi:10.1542/peds.2008-3080. （原始内容存档 (PDF)于2024-02-22）.
van Heijenoort J. Formation of the glycan chains in the synthesis of bacterial peptidoglycan. Glycobiology. March 2001, 11 (3): 25R–36R. PMID 11320055. S2CID 46066256. doi:10.1093/glycob/11.3.25r .
Balant L, Dayer P, Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. Clinical Pharmacokinetics. 1985-04-01, 10 (2): 101–143. PMID 3888488. S2CID 23478077. doi:10.2165/00003088-198510020-00001.
Hedlund E. The protective effects of β-lactam antibiotics in motor neuron disorders. Experimental Neurology. September 2011, 231 (1): 14–18. PMID 21693120. S2CID 26353910. doi:10.1016/j.expneurol.2011.06.002.
Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. January 2005, 433 (7021): 73–77. Bibcode:2005Natur.433...73R. PMID 15635412. S2CID 4301666. doi:10.1038/nature03180.

tga.gov.au

Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. Therapeutic Goods Administration (TGA). 2022-06-21 [2024-03-30]. （原始内容存档于2023-07-06）.

utah.edu

healthcare.utah.edu

FDA Updates warning on Ceftriaxone-Calcium injection. （原始内容存档于2009-11-28）.

web.archive.org

Ceftriaxone (Rocephin) Use During Pregnancy. Drugs.com. 2019-12-12 [2019-12-24]. （原始内容存档于2016-08-23）.
Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. Therapeutic Goods Administration (TGA). 2022-06-21 [2024-03-30]. （原始内容存档于2023-07-06）.
Ceftriaxone Sodium Monograph for Professionals. Drugs.com. [2016-08-27]. （原始内容存档于2016-05-31）.
Ceftriaxone- ceftriaxone sodium injection, powder, for solution. DailyMed. 2019-12-31 [2020-02-01]. （原始内容存档于2015-11-17）.
https://web.archive.org/web/20231206072711/https://www.medsafe.govt.nz/profs/datasheet/c/ceftriaxoneinjDEVA.pdf
https://web.archive.org/web/20230813180009/https://www.pbm.va.gov/PBM/vacenterformedicationsafety/nationalpbmbulletin/CeftriaxoneNationalPBMBulletin.pdf
Ceftriaxone (Rocephin): Incompatible with solutions containing calcium. （原始内容存档于2023-12-08）.
https://web.archive.org/web/20240222194630/https://www.hpra.ie/docs/default-source/Safety-Notices/ceftriaxone---march-2010---final.pdf
Ceftriaxone. Drugs and Lactation Database (LactMed®) [Internet]. 2021-01-18 [2024-08-03]. （原始内容存档于2024-06-03）.
Rocephin Prescribing Information (PDF). Roche. [2015-11-01]. （原始内容存档 (PDF)于2016-03-04）.
Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W. Ceftriaxone and acute renal failure in children (PDF). Pediatrics. April 2014, 133 (4): e917–e922 [2024-02-22]. PMID 24664092. S2CID 2854637. doi:10.1542/peds.2013-2103. （原始内容存档 (PDF)于2024-02-22）.
Guggenbichler JP, Allerberger FJ, Dierich M. Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy. Padiatrie und Padologie. 1986, 21 (4): 335–342 [2023-04-29]. PMID 3562044. （原始内容存档于2023-04-29）.
The Use of Cephalosporins in Penicillin-allergic Patients. www.medscape.com. [2015-11-10]. （原始内容存档于2015-11-14）.
FDA Updates warning on Ceftriaxone-Calcium injection. （原始内容存档于2009-11-28）.
Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events (PDF). Pediatrics. April 2009, 123 (4): e609–e613 [2024-02-22]. PMID 19289450. S2CID 22718923. doi:10.1542/peds.2008-3080. （原始内容存档 (PDF)于2024-02-22）.
DailyMed – Search Results for ceftriaxone. dailymed.nlm.nih.gov. [2015-11-04]. （原始内容存档于2016-03-06）.
Nursing Pharmacology Made Incredibly Easy!. Lippincott Williams & Wilkins. 7 March 2012: 496. ISBN 978-1-4511-4624-0. （原始内容存档于2016-06-03）.
Statement on the Clinical Trial of Ceftriaxone. The Northeast ALS Consortium (NEALS). 8 August 2012 [2013-05-10]. （原始内容存档于2013-05-28）.

worldcat.org

Di Bella S, Gatti M, Principe L. Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?. European Journal of Clinical Microbiology & Infectious Diseases. 2023-04-23, 42 (7): 917–918. ISSN 1435-4373. PMID 37119346. S2CID 258423746. doi:10.1007/s10096-023-04612-x （英语）.